SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-012524 to Ventyx Biosciences, Inc. (VTYX) (CIK 0001851194) (VTYX)

Ventyx Biosciences, Inc. (VTYX) (CIK 0001851194)
Date: Nov. 12, 2024 · CIK: 0001851194 · Accession: 0000000000-24-012524

AI Filing Summary & Sentiment

File numbers found in text: 333-283076

Date
November 12, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Ventyx Biosciences, Inc. (VTYX) (CIK 0001851194)

Letter

November 12, 2024 Raju Mohan Chief Executive Officer Ventyx Biosciences, Inc. 12790 El Camino Real, Suite 200 San Diego, CA 92130 Re:Ventyx Biosciences, Inc. Registration Statement on Form S-3 Filed November 7, 2024 File No. 333-283076 Dear Raju Mohan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Robert L. Wernli, Jr.

Show Raw Text
November 12, 2024
Raju Mohan
Chief Executive Officer
Ventyx Biosciences, Inc.
12790 El Camino Real, Suite 200
San Diego, CA 92130
Re:Ventyx Biosciences, Inc.
Registration Statement on Form S-3
Filed November 7, 2024
File No. 333-283076
Dear Raju Mohan:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Robert L. Wernli, Jr.